Comparative studies of various hyaluronic acids produced by microbial fermentation for potential topical ophthalmic applications
Source abstract
Abstract
Abstract This work presents a comparative study of various hyaluronic acids (HA) produced by fermentation of either Bacillus subtilis or Streptococcus towards the selection of an optimal molecular weight (MW) HA for the preparation of topical ophthalmic formulations. The influence of HA MW on water binding capacity, sterile filtration, rheological properties, precorneal residence time and ocular tolerance of ophthalmic solutions was investigated. Molecular weight did not affect hydration of hyaluronic acid according to differential scanning calorimetry (DSC). In general, medium MW HA (0.6–1 MDa) resulted in solutions that were superior in terms of sterile filtration and kinematic viscosity requirements compared to high MW HA (>1 MDa). Moreover, all HA‐based solutions exhibited well‐defined viscoelastic properties that depend on MW. Gamma scintigraphic data indicated that HA MW at 0.1% concentration (w/v) and HA origin did not significantly affect the corneal residence time on rabbit eyes. A 0.3% solution of high MW HA had a prolonged residence time in the precorneal area compared to a medium MW HA at the same concentration. Finally, an in vivo ocular irritation test based on confocal laser scanning ophthalmoscopy (CLSO) conclusively showed the excellent tolerance of both Bacillus‐derived HA and Streptococcus‐derived HA after topical instillation onto the corneal surface. Overall, this comprehensive work highlights the superiority of medium MW hyaluronic acid for topical ophthalmic formulations based on their physico‐chemical and biological properties, tolerance and handling. Such solutions are expected to enhance tear film stability, to allow for maximum comfort, and to exhibit high residence times, while being biocompatible and easy to sterile filter. © 2009 Wiley Periodicals, Inc. J Biomed Mater Res, 2010
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Ocular Surface and Contact Lens · Proteoglycans and glycosaminoglycans research · Advanced Drug Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (50)
Show source-provided references
1. Felt O · 2002 · 377
2. Polyacrylic acid gel in patients with dry eyes: a randomised comparison with polyvinyl alcohol10.1177/112067219800800206 ↗
3. Carbomer gels in dry eye treatment: Literature review
4. 10.1038/sj.eye.670016910.1038/sj.eye.6700169 ↗
5. 10.1076/ceyr.28.1.55.2349510.1076/ceyr.28.1.55.23495 ↗
6. 10.1006/exer.1998.065610.1006/exer.1998.0656 ↗
7. Lubricant eye drops for contact lens wearers
8. 10.1007/BF0092093910.1007/BF00920939 ↗
9. 10.1016/0378-5173(84)90229-110.1016/0378-5173(84)90229-1 ↗
10. 10.1097/00003226-199207000-0000310.1097/00003226-199207000-00003 ↗
11. Evaluation of sodium hyaluronate as viscous vehicle for eye drops
12. 10.3109/0271368870903484410.3109/02713688709034844 ↗
13. 10.1096/fasebj.6.7.156359210.1096/fasebj.6.7.1563592 ↗
14. Balazs EA · 1992 · 480
15. Balazs EA · 1998 · 325
16. Chemical properties of contact lens rewetters. A review on hyaluronic acid as a contemporary ingredient in contact lens rewetters
17. 10.1136/bjo.86.8.87910.1136/bjo.86.8.879 ↗
18. 10.1159/00005084210.1159/000050842 ↗
19. 10.1136/bjo.83.10.112110.1136/bjo.83.10.1121 ↗
20. 10.1097/00003226-199309000-0001010.1097/00003226-199309000-00010 ↗
21. Sodium hyaluronate eye drops enhance tear film stability
22. Berriaud N · 1998 · 313
23. 10.1089/jop.1994.10.8310.1089/jop.1994.10.83 ↗
24. 10.1016/0169-409X(93)90016-W10.1016/0169-409X(93)90016-W ↗
25. 10.1016/0378-5173(89)90193-210.1016/0378-5173(89)90193-2 ↗
26. 10.1016/S0021-5155(02)00541-510.1016/S0021-5155(02)00541-5 ↗
27. 10.1016/0014-4835(91)90110-Z10.1016/0014-4835(91)90110-Z ↗
28. 10.1007/s00253-004-1774-410.1007/s00253-004-1774-4 ↗
29. BalazsEA. Ultra pure high molecular wt. hyaluronic acid—Is non‐antigenic and used as synthetic aq. humour and synovial fluid as nerve tissue and wound protector and drug carrier. US patent 4 141 973;1979.
30. WidnerW SlomaA ThomasM TangM. Producing a hyaluronic acid by cultivatingBacilluscell comprising a nucleic acid construct comprising a variant amyL promoter a consensus promoter and a cryIIIA promoter and isolating hyaluronic acid from the cultivation medium. WO patent application 2005098016‐A2;2005.
31. 10.3109/0363904900911490710.3109/03639049009114907 ↗
32. 10.1023/B:JTAN.0000033213.31447.1d10.1023/B:JTAN.0000033213.31447.1d ↗
33. 10.1007/BF0141038710.1007/BF01410387 ↗
34. 10.1016/0008-6215(94)00147-210.1016/0008-6215(94)00147-2 ↗
35. 10.1016/0144-8617(95)98837-710.1016/0144-8617(95)98837-7 ↗
36. 10.1016/0378-5173(92)90279-B10.1016/0378-5173(92)90279-B ↗
37. 10.1136/bjo.70.6.44210.1136/bjo.70.6.442 ↗
38. 10.1002/jps.260064081110.1002/jps.2600640811 ↗
39. 10.1016/0378-5173(91)90051-O10.1016/0378-5173(91)90051-O ↗
40. Acceptability of thickened eye drops to human subjects
41. 10.1002/jbm.a.3062310.1002/jbm.a.30623 ↗
42. Bothner Wik H · 1998 · 25
43. 10.1081/MA-10010157810.1081/MA-100101578 ↗
44. 10.1002/bip.1968.36006060310.1002/bip.1968.360060603 ↗
45. Evaluation of polysaccharides intended for ophthalmic use in ocular dosage forms
46. 10.3233/BIR-1994-3130210.3233/BIR-1994-31302 ↗
47. 10.1007/BF0091848110.1007/BF00918481 ↗
48. 10.1016/S0378-5173(99)00003-410.1016/S0378-5173(99)00003-4 ↗
49. 10.1016/S0378-5173(00)00540-810.1016/S0378-5173(00)00540-8 ↗
50. KälinP.Contribution à la validation d'un test de tolérance oculaire sur la souris. Ph.D. thesis Lausanne 1994.